000			02107na a2200229 4500
003			H12O
005			20180417112636.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aVivanco Martínez, José Luis _9815 _ePediatría
245	0	0	_aMethotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. _h[artículo]
260			_bThe Pharmacogenomics Journal, _c2012
300			_a12(5):379-85.
500			_aFormato Vancouver: Salazar J, Altés A, del Río E, Estella J, Rives S, Tasso M, et aI. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. 2012 Oct;12(5):379-85.
501			_aPMID: 21747412.
504			_aContiene 28 referencias
520			_aRecent advances in treatment for childhood acute lymphoblastic leukaemia (ALL) have significantly increased outcome. High-dose methotrexate (MTX) is the most commonly used regimen during the consolidation period, but the optimal dose remains to be defined. We investigated the usefulness of the MTHFR genotype to increase the MTX dosage in the consolidation phase in 141 childhood ALL patients enrolled in the ALL/SHOP-2005 protocol. We also investigated the pharmacogenetic role of polymorphisms in genes involved in MTX metabolism on therapy-related toxicity and survival. Patients with a favourable MTHFR genotype (normal enzymatic activity) treated with MTX doses of 5 g m-2 had a significantly lower risk of suffering an event than patients with an unfavourable MTHFR genotype (reduced enzymatic activity) that were treated with the classical MTX dose of 3 g m-2 (P ¼ 0.012). Our results indicate that analysis of the MTHFR genotype is a useful tool to optimise MTX therapy in childhood patients with ALL.
710			_9446 _aServicio de Pediatría-Neonatología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/8/pc8412.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c8412 _d8412